Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma
Open Access
- 17 February 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (4) , 1395-1399
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Clinical Outcomes after Teclistamab Failure in Relapsed/Refractory Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2025
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaJournal of Clinical Oncology, 2025
- Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy ConsortiumBlood Cancer Discovery, 2025
- Radiation therapy to manage isolated relapse after chimeric antigen receptor T-cell therapy in multiple myelomaHaematologica, 2025
- Management of oligoprogressive and oligopersistent disease in advanced NSCLC.2025
- Incorporating radiation with anti‐CD19 chimeric antigen receptor T‐cell therapy for relapsed/refractory non‐Hodgkin lymphoma: A multicenter consensus approachAmerican Journal of Hematology, 2023
- Upfront Radiation Therapy (RT) for Post-Stem Cell Transplant Multiple Myeloma (MM) Patients with Oligo-Relapse/Progressive Disease: Factors Associated with Favorable OutcomesBlood, 2023
- International uniform response criteria for multiple myelomaLeukemia, 2006